{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:29:37Z","timestamp":1775233777184,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,9,1]]},"DOI":"10.1038\/sj.leu.2403058","type":"journal-article","created":{"date-parts":[[2003,9,11]],"date-time":"2003-09-11T14:47:26Z","timestamp":1063291646000},"page":"1914-1915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Thalidomide therapy induces response in relapsed mantle cell lymphoma"],"prefix":"10.1038","volume":"17","author":[{"given":"G","family":"Damaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Lefr\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Varet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Furman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,9,10]]},"reference":[{"key":"BF2403058_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587\u2013593.","journal-title":"Leukemia"},{"key":"BF2403058_CR2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565\u20131571.","journal-title":"N Engl J Med"},{"key":"BF2403058_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.leu.2402866","volume":"17","author":"SV Rajkumar","year":"2003","unstructured":"Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775\u2013779.","journal-title":"Leukemia"},{"key":"BF2403058_CR4","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","volume":"15","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274\u20131276.","journal-title":"Leukemia"},{"key":"BF2403058_CR5","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","volume":"341","author":"N Raje","year":"1999","unstructured":"Raje N, Anderson K . Thalidomide a revival story. N Engl J Med 1999; 341: 1606\u20131609.","journal-title":"N Engl J Med"},{"key":"BF2403058_CR6","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D'Amato","year":"1994","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082\u20134085.","journal-title":"Proc Natl Acad Sci"},{"key":"BF2403058_CR7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380\u2013386.","journal-title":"J Immunol"},{"key":"BF2403058_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","volume":"187","author":"PAJ Haslett","year":"1998","unstructured":"Haslett PAJ, Corral LG, Albert M, Kaplan G . Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885\u20131892.","journal-title":"J Exp Med"},{"key":"BF2403058_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210\u2013216.","journal-title":"Blood"},{"key":"BF2403058_CR10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1189\/jlb.72.5.939","volume":"72","author":"M Mohty","year":"2002","unstructured":"Mohty M, Stoppa AM, Blaise D, Isnardon D, Gastaut JA, Olive D et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukocute Biol 2002; 72: 939\u2013945.","journal-title":"J Leukocute Biol"},{"key":"BF2403058_CR11","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","volume":"276","author":"JA Keifer","year":"2001","unstructured":"Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr. AS . Inhibition of NF-\u03baB Activity by Thalidomide through Suppression of I\u03baB Kinase Activity. J Biol Chem 2001; 276: 22382\u201322387.","journal-title":"J Biol Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403058","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T17:39:58Z","timestamp":1704908398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,1]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9,1]]}},"alternative-id":["BF2403058"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403058","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,1]]},"assertion":[{"value":"10 September 2003","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}